Clinical Trials
163 trialsNCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT06661902 2026-02-17
BURN
University of Washington
Phase 1/2 Completed
NCT01543659 2026-02-13
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04019327 2025-12-15
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01089387 2025-12-04
INSTIN
Institut National de la Santé Et de la Recherche Médicale, France
Phase 1/2 Completed
NCT01147965 2025-11-25
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
NantCell, Inc.
Phase 1/2 Completed
NCT03493945 2025-09-30
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05230251 2025-09-12
ROADSTER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2 Completed
NCT02769962 2025-07-28
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05253053 2025-06-12
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT06389695 2025-05-21
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
Norroy Bioscience Co., LTD
Phase 1/2 Completed
NCT01848067 2025-05-04
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Thomas Jefferson University
Phase 1/2 Completed
NCT03888612 2025-04-01
mCRPC
Arvinas Inc.
Phase 1/2 Completed
NCT04487847 2025-01-16
PICture
Radboud University Medical Center
Phase 1/2 Completed
NCT03518606 2025-01-15
MOVIE
UNICANCER
Phase 1/2 Completed
NCT06398470 2025-01-10
Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy
University College, London
Phase 1/2 Completed
NCT01784913 2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2 Completed
NCT01284920 2024-11-21
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Astellas Pharma Inc
Phase 1/2 Completed
NCT01774071 2024-10-02
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02933255 2024-05-31
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04742959 2024-04-26
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT02325557 2024-04-02
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis, Inc.
Phase 1/2 Completed
NCT00946881 2024-02-07
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 1/2 Completed
NCT03949517 2024-01-30
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
Phase 1/2 Completed
NCT00915122 2023-12-06
Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate
University Health Network, Toronto
Phase 1/2 Completed
NCT03513211 2023-11-22
HITMAN-PC
St Vincent's Hospital, Sydney
Phase 1/2 Completed
NCT05516329 2023-09-21
Study of 18F-Thretide PET/CT in Patients With Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Completed
NCT01485861 2023-09-14
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Genentech, Inc.
Phase 1/2 Completed
NCT04614363 2023-08-28
68 Ga-PSMA for High Risk Prostate Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT02499835 2023-08-01
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 1/2 Completed
NCT00987753 2023-05-25
Study Evaluating the Safety and Tolerability of L-377202
University of Alabama at Birmingham
Phase 1/2 Completed
NCT01278914 2023-05-08
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
Oslo University Hospital
Phase 1/2 Completed
NCT00547339 2022-12-07
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT00188695 2022-10-07
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
University Health Network, Toronto
Phase 1/2 Completed
NCT04685811 2022-09-22
Evaluation of PSMA Antagonist Produced by Two Different Methods
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT02012296 2022-07-13
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
University of Chicago
Phase 1/2 Completed
NCT02121639 2022-05-05
ProCAID
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT01861496 2022-02-24
LiPlaCis
Allarity Therapeutics
Phase 1/2 Completed
NCT02001623 2021-12-29
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT02711956 2021-11-30
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 1/2 Completed
NCT02280317 2021-11-08
VAL201-001
ValiRx Plc
Phase 1/2 Completed
NCT04555343 2021-11-05
Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention
Fraser Health
Phase 1/2 Completed
NCT01505868 2021-07-30
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed